
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026
Oculis Holding AG announced it will present its neuroprotective drug candidate Privosegtor at the Clinical Trials at the Summit 2026 in Las Vegas. Privosegtor, designed to treat optic neuritis and other optic neuropathies, has shown promising Phase 2...
